RZLT
Rezolute, Inc.2.0200
+0.3900+23.9%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
187.31MP/E (TTM)
-Basic EPS (TTM)
-0.94Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Rezolute posted a Q2 FY2026 operating loss of $24.2M, up 42% y/y from $17.1M, driven by ersodetug clinical costs, $1.5M severance from workforce cuts, and higher G&A for commercial prep—yet net loss narrowed to $22.8M from $15.7M on steady interest income. Six-month operating loss hit $44.0M (up 30% y/y), with R&D up 8% on compensation while ersodetug spend fell; cash burn quickened to $37.8M from $29.7M. Cash and marketable securities total $132.9M, funding trials for 12+ months. No debt. SunRIZE Phase 3 missed endpoints. Litigation risk looms from trial results.
8-K
Q2 loss widens; sunRIZE misses
Rezolute reported Q2 fiscal 2026 results on February 12, 2026, with cash at $132.9 million down from $167.9 million at June 30, 2025, and net loss widening to $22.8 million from $15.7 million year-over-year amid higher R&D and G&A from clinical trials and layoffs. sunRIZE Phase 3 for congenital HI missed primary endpoints but showed drug activity; all participants rolled into extension. upLIFT tumor HI trial advances, topline due H2 2026. FDA meeting looms.
8-K
sunRIZE misses endpoints, EAP shines
Rezolute disclosed Phase 3 sunRIZE results in congenital HI, missing primary and key secondary endpoints on hypoglycemia events and time despite pharmacologic activity and biomarker responses matching Phase 2. Yet 75% of 9 tumor HI EAP patients quit IV dextrose/TPN. All 59 sunRIZE completers rolled into OLE. FDA meeting set for Q1 2026; upLIFT topline in 2H 2026.
8-K
Annual meeting elects directors
Rezolute held its 2026 annual meeting on November 19, 2025, electing all seven director nominees amid significant withhold votes for Nerissa Kreher and Wladimir Hogenhuis. Stockholders ratified Grant Thornton as auditors, approved executive pay by a slim margin, and boosted the 2021 Stock Incentive Plan shares to 21,950,000. Directors won. Equity pool expansion signals talent retention push.
8-K
Ersodetug program update
Rezolute hosted an investor event on November 10, 2025, updating on the ersodetug development program for congenital and tumor hyperinsulinism. Experts detailed unmet needs in HI, Phase 3 programs (sunRIZE, RIZE, upLIFT), and a combined U.S. market of 4,500 patients. Real-world EAP data showed 13 tumor HI patients improving enough to resume tumor therapies. Forward-looking statements carry risks per SEC filings.
ALT
Altimmune, Inc.
5.03-0.25
CORT
Corcept Therapeutics Incorporat
81.12-6.18
DRMA
Dermata Therapeutics, Inc.
2.32-0.16
GUTS
Fractyl Health, Inc.
2.16-0.08
RNTX
Rein Therapeutics, Inc.
1.35-0.13
RNXT
RenovoRx, Inc.
0.84-0.10
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
RYTM
Rhythm Pharmaceuticals, Inc.
112.45-0.07
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SLNO
Soleno Therapeutics, Inc.
49.50-0.45